Immunotherapy for stomach (gastric) cancer
Stomach or Gastric cancer immunotherapy in Israel is a treatment with drugs that activate the immune system to fight cancer cells.
Stomach cancer (adenocarcinoma) remains the fifth most common malignant disease in the world. One of the most common causes is infection with H. pylori bacteria.
Traditional treatments are ineffective against advanced stomach cancer; immunotherapy has shown the potential to help such patients.
The FDA has approved several drugs for treating stomach cancer in Israel:
• Trastuzumab (Herceptin Herceptin) – the target antibody for HER2. Trastuzumab is only effective for people with stomach cancer with high levels of protein called HER2. Statistically, this treatment will fit about 20% of stomach cancer patients. Trastuzumab binds to HER2 proteins on the cancerous cells, thus stopping cell division. Patients with advanced gastric cancer are sometimes treated concomitantly with chemotherapy with Trastuzumab. If the drug is effective, our doctor may decide to continue treatment even after chemotherapy is finished. The side effects of Trastuzumab are usually quite mild.
• Ramucirumab (Cyramza Cyramza) – the target antibody for VEGFR2
• Pembrolizumab (Keytruda) – a control point immunotherapy against PD-1, has also been approved for patients with metastatic PD-L1-positive gastric cancer.
Currently, several other immunotherapeutic drugs are being tested, including control point inhibitors, CAR T cells, and multiple antibody approaches. Additional treatments may be available in clinical trials. It is advisable to consult your attending physician about clinical trials for immunotherapy of stomach cancer.
Immunotherapy drugs are also used in Israel for a personalized treatment regimen for each patient with stomach cancer.
Our doctors prescribe personalized treatment based on the results of new molecular genetic tests, during which the genetic profile of the tumor is compiled.